Cargando…
Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails
BACKGROUND: Natalizumab (NAT), a humanized monoclonal antibody, which binds in both α(4)β(1) integrins and α(4)β(7) integrins, is approved for the treatment of multiple sclerosis (MS) and Crohn's disease (CD). An uncommon but serious adverse event from NAT treatment is known as progressive mult...
Autores principales: | Li, Hao, Shi, Fang-Hong, Huang, Shi-Ying, Zhang, Shun-Guo, Gu, Zhi-Chun, Wei, Ji-Fu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076155/ https://www.ncbi.nlm.nih.gov/pubmed/29995817 http://dx.doi.org/10.1097/MD.0000000000011507 |
Ejemplares similares
-
Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors: Protocol for a systematic review and meta-analysis
por: Li, Hao, et al.
Publicado: (2018) -
Assessment of pain between sedated and unsedated colonoscopy: Double-blind randomized clinical trail
por: Shavakhi, Ahmad, et al.
Publicado: (2021) -
Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta‐Analysis of 4894 Patients From 24 Randomized Double‐Blind Placebo‐Controlled Clinical Trials
por: Wei, Anhua, et al.
Publicado: (2016) -
Clinical Efficacy of the Chinese Herbal Medicine Shumian Capsule for Insomnia: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Chen, Suzhen, et al.
Publicado: (2022) -
Safety and antifatigue effect of Korean Red Ginseng capsule: A randomized, double-blind and placebo-controlled clinical trial
por: Yang, Yi, et al.
Publicado: (2022)